Assessing perceived adverse effects of biologic medications for patients with psoriasis - 17/01/20
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Funding sources: None. |
|
Disclosure: Dr Feldman has received research, speaking, and/or consulting support from a variety of companies, including Galderma, GlaxoSmithKline/Stiefel, Almirall, Leo Pharma, Baxter, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Taro, AbbVie, Cosmederm, Anacor, Astellas, Janssen, Lilly, Merck, Merz, Novartis, Regeneron, Sanofi, Novan, Parion, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment. Mr Bray and Drs Cline and Feldman have no conflicts of interest to declare. |
|
IRB approval status: Reviewed and approved by Wake Forest School of Medicine IRB (IRB00057820). |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?